Literature DB >> 10146871

The role of insurance claims databases in drug therapy outcomes research.

N J Lewis1, J T Patwell, B A Briesacher.   

Abstract

The use of insurance claims databases in drug therapy outcomes research holds great promise as a cost-effective alternative to post-marketing clinical trials. Claims databases uniquely capture information about episodes of care across healthcare services and settings. They also facilitate the examination of drug therapy effects on cohorts of patients and specific patient subpopulations. However, there are limitations to the use of insurance claims databases including incomplete diagnostic and provider identification data. The characteristics of the population included in the insurance plan, the plan benefit design, and the variables of the database itself can influence the research results. Given the current concerns regarding the completeness of insurance claims databases, and the validity of their data, outcomes research usually requires original data to validate claims data or to obtain additional information. Improvements to claims databases such as standardisation of claims information reporting, addition of pertinent clinical and economic variables, and inclusion of information relative to patient severity of illness, quality of life, and satisfaction with provided care will enhance the benefit of such databases for outcomes research.

Entities:  

Mesh:

Year:  1993        PMID: 10146871     DOI: 10.2165/00019053-199304050-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  29 in total

1.  The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization.

Authors:  B L Harris; A Stergachis; L D Ried
Journal:  Med Care       Date:  1990-10       Impact factor: 2.983

2.  Prescription cost sharing: economic and health impacts, and implications for health policy.

Authors:  R A Levy
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

3.  Panel IV. Evaluation: the value and cost-effectiveness of drug utilization review programs.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  1991-11       Impact factor: 6.875

4.  A chronic disease score from automated pharmacy data.

Authors:  M Von Korff; E H Wagner; K Saunders
Journal:  J Clin Epidemiol       Date:  1992-02       Impact factor: 6.437

5.  The demand for prescription drugs as a function of cost-sharing.

Authors:  A Leibowitz; W G Manning; J P Newhouse
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

6.  Physician utilization disparities between the uninsured and insured. Comparisons of the chronically ill, acutely ill, and well nonelderly populations.

Authors:  C Hafner-Eaton
Journal:  JAMA       Date:  1993-02-10       Impact factor: 56.272

7.  Choice of payment plan in the Medicare capitation demonstration.

Authors:  S A Garfinkel; W E Schlenger; K R McLeroy; F A Bryan; B J York; G H Dunteman; A S Friedlob
Journal:  Med Care       Date:  1986-07       Impact factor: 2.983

8.  Accuracy of the death certificate in a population-based study of asthmatic patients.

Authors:  L W Hunt; M D Silverstein; C E Reed; E J O'Connell; W M O'Fallon; J W Yunginger
Journal:  JAMA       Date:  1993-04-21       Impact factor: 56.272

9.  Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland.

Authors:  J S Weissman; C Gatsonis; A M Epstein
Journal:  JAMA       Date:  1992-11-04       Impact factor: 56.272

10.  Influence of age, sex, and race on prescription drug use among Georgia Medicaid recipients.

Authors:  L Kotzan; N V Carroll; J A Kotzan
Journal:  Am J Hosp Pharm       Date:  1989-02
View more
  13 in total

1.  Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population.

Authors:  L T Piecoro; M Potoski; J C Talbert; D E Doherty
Journal:  Health Serv Res       Date:  2001-06       Impact factor: 3.402

Review 2.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

Review 3.  Costs, innovation and efficiency in anti-infective therapy.

Authors:  J L Bootman; R J Milne
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

4.  Necessity of using intermediate outcome to proxy long term effects. The example of thrombolytics.

Authors:  J S Schwartz
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

5.  A survey of population-based drug databases in Canada.

Authors:  E Miller; B Blatman; T R Einarson
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

6.  Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials?

Authors:  Ulrich Guller
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

7.  Key considerations when using health insurance claims data in advanced data analyses: an experience report.

Authors:  Renata Konrad; Wenchang Zhang; Margrét Bjarndóttir; Ruben Proaño
Journal:  Health Syst (Basingstoke)       Date:  2019-03-01

Review 8.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

9.  Using healthcare claims data for outcomes research and pharmacoeconomic analyses.

Authors:  H G Birnbaum; P Y Cremieux; P E Greenberg; J LeLorier; J A Ostrander; L Venditti
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 10.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.